Whalesbook
Aether Industries announced its fourth quarter and full fiscal year 2026 results, reporting a robust year.
Key Financial Highlights
- FY26 Revenue: INR 11,601 million (38% increase year-over-year)
- FY26 EBITDA: INR 3,547 million (53% increase year-over-year)
- FY26 Profit After Tax (PAT): INR 2,195 million (39% increase year-over-year)
While the full-year figures show strong growth, the fourth quarter of FY26 saw a sequential decrease in revenue and EBITDA compared to the third quarter. This dip was attributed to specific one-off events and an inventory write-off following a fire incident at one of its facilities. Management noted the fire incident had minimal impact, with no injuries or significant losses.
Growth Drivers and Future Strategy
The company's annual performance was driven by its Large Scale Manufacturing (LSM) and Contract Research and Manufacturing Services (CRAMS) segments. Aether Industries is investing in expanding its manufacturing capacity at Site 4 and developing new products at Site 5. The strategy focuses on enhancing its chemistry capabilities, securing global clients, developing complex molecules, and reinvesting cash flow into research and development (R&D) and capital expenditures. By FY30, CRAMS and contract exclusive manufacturing (CEM) are projected to account for over 70% of the company's revenue.
Upcoming Milestones and Financial Outlook
Commercialization of Phase 1 at Site 5 is expected to be a significant growth catalyst in FY27. Aether Industries aims to improve its working capital cycle to around 160 days by FY27, down from the current 179 days. Capital expenditure for FY27 is planned between INR 3,000 to INR 3,500 million, covering Site 5 and a new R&D facility. To finance these expansion projects, debt levels are anticipated to increase.
Potential Challenges
Investors should monitor the increasing debt levels as the company funds its expansion plans. The Q4 sequential decline, though linked to specific events, highlights potential operational risks. Management aims to maintain EBITDA margins between 29-30% and PAT margins around 19-20% for FY27.